Investing in Tomorrow's Innovations

Ingenious Global Venture Partners (IGVP) is a life-sciences and healthcare-focused venture studio managed by strong network (healthcare professionals, industry veterans and investors) with extensive operational and strategic experience.

• Mission: To create or identify impact-driven ventures that offer significant market opportunities by addressing critical clinical unmet needs through the development and investment in breakthrough medical technologies.

• Focus: Digital health, life science research tools, molecular diagnostics, digital therapeutics, synthetic biology, therapeutics discovery, development, and manufacturing (small and large molecule, as well as cell/gene therapy), microbiome and med-device/med-tech.

The problem

Life sciences and healthcare are enormous industries with significant unmet needs and a proven inability to innovate. Globally, there is no shortage of demand for better healthcare, and there is no shortage of ideas for life science innovations. However, in the case of life science, the private sector struggles to scale new companies (high costs, long development cycles, high failure rates, intense competition and investor pressures) and, in the case of healthcare (integration, adoption, payor, regulatory, compliance and competitive pressures) the private sector struggles to improve actual patient outcomes.

The opportunity

We believe there are three interrelated issues:

1. A high level of complexity, both scientific, technical, operational, financial, and strategic (solved with the right people)

2. A lack of appropriate support models (solved with a new Venture Studio model – Ingenious Global Venture Partners)

3. Untapped opportunities for geographic arbitrage (solved with our footprint)

Seizing the opportunity

What’s needed is the right expertise, the right support model, and a way to run international playbooks. What we are sitting on is

1. The right network of experienced team and work at the intersection of biopharma and biotools as well as the intersection of devices and healthcare delivery (including digital health solutions and healthcare payor/provider innovations)

2. Ability for IGVP to incubate new ideas as well as [co-build ideas with founders that can benefit from our seasoned network]; 

3. A footprint to allow companies to get traction in the US, with feasibility to do high-value development, clinical trials and rapid prototyping in the EU/ Asia including India. 

The IGVP Model: An Ideal Co-Founder

IGVP will operate with a “stage-gate” approach, a disciplined process that is a reality check for a startup’s progress. This is particularly important because founders often fall in love with their ideas and can’t maintain objectivity. The IGVP studio model, with its majority ownership, provides the structure to have difficult but necessary conversations about a company’s thesis and results. This helps prevent founders from burning through money over 12 to 18 months on an idea that isn’t working.

A key part of IGVP studio’s operational expertise is capital efficiency. This involves making smart decisions and knowing when to make another bet or to say “no”. This data-driven approach is critical for IGVP that will aim to scale, as emotional decision-making is not sustainable when managing a large portfolio of companies.

As IGVP co-founder role we consider the four key “customers” IGVP must serve: 

- The investors, 

- The IGVP team (operational & strategic leadership executives), 

- The start-ups, entrepreneurs, university and health system partners with, and

- The follow-on capital providers and exit partners. 

This framework helps IGVP tailor its process, playbook and support system to its unique goals and exit focus.

Why work with us?

For would-be founders / ideas generated in-house

· Access to expertise (fractional support)

· Access to a roadmap and playbooks

· Access to capital through our investor network 

For founders

· Access to expertise (fractional support)

· Access to a roadmap and playbooks

· Access to capital through our investor network 

· Opportunity to accelerate what they’ve got or re-boot based on stage-gating process and milestones

For investors

· Exposure to a meaningful asset class; 

· Access to triaged deal flow 

· Our network: Scientific, medical, impact investors; 

· Engaged community in a rapidly evolving, complex, uncertain space 

For people who want to work with IGVP

· A chance to do what they want to do but with more companies

· Part of the community that helps evaluate and create ventures with innovative patient focused solutions  

Our Process: 

We built a disciplined private-equity style approach to R&D and healthcare delivery so  companies focus to consistently deliver faster, more substantial gains, revenue and exit ready often transforming their performance within just a few years. Our playbook consists of six practices: 

1. conducting full-potential due diligence on a recurring basis, 

2. building management teams from IGVP network (interim, fractional or full-time executives) that are precisely matched to their value-creation goals, 

3. Fit for purpose labor allocation to streamline operations and boost productivity, 

4. Periodic customer/ market validation while executing transformation plans with granular accountability, and treating leadership time as a scarce, high-value asset. 

5. Applied together, these methods foster sharper strategic focus, quicker decision-making, and stronger alignment between resources and results. 

6. IGVP network leadership including business development leaders adopts to accelerate growth, improve efficiency, strengthen long-term performance and partnerships for exit.

Biotech & MedTech focus: We partner with surgeons, clinicians, university professors and entrepreneurs to bring their ideas to market. We build independent companies, providing milestone-driven product development approach that helps securing funding while executing on strategic plans and builds partnerships. We provide guidance from ideation, validation, company building, operational support, strategic leadership, clinical R&D trial planning, access to network (physicians, regulatory, reimbursement, health systems) and investor readiness support. 

Biotools: IGVP looks to smaller, innovative LST assets, focusing on companies in high-growth precision medicine areas of research and development (R&D) strong activity in laboratory automation and sample-focused workflows, with a continued emphasis on omics applications. 

We welcome you to partner with Ingenious Global Venture Partners to fundamentally change the startup landscape, offering a new model that combines the strategic focus of private equity with the high-velocity world of early-stage healthcare and life-sciences company building. We believe this impact driven patient-centric innovation will empower founders to launching, de-risking and scaling new ventures.

Schedule Call: https://calendar.app.google/rRwLBWFTFHxgsS1n9

DISCLOSURE

Ingenious Global Venture Partners is not a registered broker-dealer, investment advisor, or financial institution, and is not licensed by the Financial Industry Regulatory Authority (FINRA) or any other regulatory authority. The services provided by Ingenious Global Venture Partners are for informational and advisory purposes only and do not constitute investment advice, legal advice, or recommendations to buy, sell, or trade any securities.